MedTrace Logo

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

NCT05841160 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2023-06-09

No results posted yet for this study

Summary

THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION

Conditions

  • QT/QTc

Interventions

DRUG

Ecopipam Hydrochloride

oral tablets

DRUG

Moxifloxacin

oral tablet

DRUG

Placebo

oral tablet

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • Clario

    collaborator UNKNOWN

  • Emalex Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2023-05-07
Completion
2023-05-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05841160 on ClinicalTrials.gov